AAD Annual Meeting 2026: key results and trends

IGA0/1 (clear/minimal) and PASI90 response rates improved through W48 and were maintained at ~70% through W100 in the guselkumab-randomized and placebo-guselkumab groups.

mNAPSI 75 response rate to tildrakizumab increased from 25.5% at W28 to 41.2% at W52; 76.9% of W28 responders sustained response at W52.

ICO demonstrated higher IGA 0/1 response rates vs PBO at W16 (67.5% vs 9.2%); treatment effect (proportion difference: 57.9% [95%CI:53.8–61.6%]) was consistent across subgroups (range:51.8–64.2%).

At Year1, 55.8%/57.4% bimekizumab-treated vs 26.7% ustekinumab-treated/40.8% secukinumab-treated patients achieved remission.

Of patients receiving abrocitinib 100 or 200 mg monotherapy, 2.5% and 5.6% achieved MDA at Week 2 versus 0.0% receiving placebo; dose-dependent responses increased at Week 12 (100 mg: 20.7%; 200 mg: 35.7%).

Rates of AEs and SAEs through W16 were similar with deucravacitinib and placebo regardless of concomitant use of methotrexate (AEs: no, 64.6% vs 51.1%; yes, 59.3% vs 51.3%; SAEs: no, 2.3% vs 1.9%; yes, 1.6% vs 1.6%).

Treatment with APG777 was well-tolerated and led to an overall EASI-75 response rate of 74.7% (n=56/75) at Week 16 (vs. 26.3% [n=10/38] placebo; p<0.001).

At Week 16, patients receiving lutikizumab showed improvement in percent change from baseline in AN count (-70.8%) and draining tunnels (-84.8%).

Percentage change in PASI from baseline was -96.6% and -98.6% with SHR-1139 100 and 300 mg (vs 0 with placebo).